These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28052121)

  • 1. Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.
    Marcussen M; Bødker JS; Christensen HS; Johansen P; Nielsen S; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
    PLoS One; 2017; 12(1):e0169286. PubMed ID: 28052121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients.
    Milstein DM; te Boome LC; Cheung YW; Lindeboom JA; van den Akker HP; Biemond BJ; Ince C
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan; 109(1):91-7. PubMed ID: 20123381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.
    Rodrigues GH; Jaguar GC; Alves FA; Guollo A; Camandoni VO; Damascena AS; Lima VCC
    Lasers Med Sci; 2017 Jul; 32(5):1089-1095. PubMed ID: 28512727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
    J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J; Seabrook J; Fulford A; Rajakumar I
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
    de Paula Eduardo F; Bezinelli LM; da Graça Lopes RM; Nascimento Sobrinho JJ; Hamerschlak N; Correa L
    Hematol Oncol; 2015 Sep; 33(3):152-8. PubMed ID: 24519448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Lilleby K; Garcia P; Gooley T; McDonnnell P; Taber R; Holmberg L; Maloney DG; Press OW; Bensinger W
    Bone Marrow Transplant; 2006 Jun; 37(11):1031-5. PubMed ID: 16633359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
    McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
    Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febrile mucositis in haematopoietic SCT recipients.
    van der Velden WJ; Blijlevens NM; Feuth T; Donnelly JP
    Bone Marrow Transplant; 2009 Jan; 43(1):55-60. PubMed ID: 18762766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of high dose L-PAM-induced mucositis by cryotherapy.
    Dumontet C; Sonnet A; Bastion Y; Salles G; Espinouse D; Coiffier B
    Bone Marrow Transplant; 1994 Sep; 14(3):492-4. PubMed ID: 7994283
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma.
    Sharma SK; Handoo A; Choudhary D; Dhamija G; Gupta N
    World J Gastroenterol; 2013 Feb; 19(5):784-5. PubMed ID: 23429569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis.
    Mori T; Aisa Y; Yamazaki R; Mihara A; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2006 Nov; 38(9):637-8. PubMed ID: 16953203
    [No Abstract]   [Full Text] [Related]  

  • 17. GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.
    Coleman EA; Lee JY; Erickson SW; Goodwin JA; Sanathkumar N; Raj VR; Zhou D; McKelvey KD; Apewokin S; Stephens O; Enderlin CA; Vangsted AJ; Reed PJ; Anaissie EJ
    Support Care Cancer; 2015 Mar; 23(3):841-9. PubMed ID: 25218607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
    Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
    Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma.
    Marcussen M; Sønderkær M; Bødker JS; Andersen M; Nielsen S; Vesteghem C; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
    PLoS One; 2018; 13(1):e0190709. PubMed ID: 29338018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.
    Cho YK; Sborov DW; Lamprecht M; Li J; Wang J; Hade EM; Gao Y; Tackett K; Williams N; Benson DM; Efebera YA; Rosko AE; Devine SM; Poi M; Hofmeister CC; Phelps MA
    Clin Pharmacol Ther; 2017 Sep; 102(3):511-519. PubMed ID: 28160288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.